Past issues are only available to subscribers. If you are not a member, click here to join.

ISSUE 10 – MARCH 11, 2016PDF



CMS Experiment Targets Incentive To Use the Most Expensive Drug

Is Average Sales Price plus 6 percent the right amount to pay doctors under the Medicare Part B program?

Would a smaller margin diminish what may be an incentive for doctors to prescribe the most expensive drugs on the market? With clinical performance being equal, or close enough to equal, is it not better for the doctor’s wallet to bill 6 percent of the highest possible ASP available?

In a move that immediately set off an explosion in the cancer field, the Centers for Medicare and Medicaid Services announced a proposed rule to test new models to improve Part B payment for prescription drugs.

 

Slamming the Door

Part VII: DePinho’s Stock Tip Revisited

On May 25, 2012, I received an email from Len Zwelling:

Paul: It can’t get worse than having our President pushing his own stock on TV. Len.

I clicked on the provided link to CNBC. What I saw was indeed difficult to process: a video of Ron DePinho, extolling the virtues of the stock of AVEO Pharmaceuticals Inc., a company he co-founded.

National Academy of Medicine Calls for Integrated FDA-CMS Pathway for Biomarker Tests

The National Academy of Medicine listed 10 goals for advancing the appropriate use of biomarker tests in precision medicine.

“How do we ensure patients have timely access to appropriate tests that may accurately direct targeted therapies, while at the same time protecting them from potential harm due to the adoption of poorly validated tests or inappropriately used tests?” the report asked, saying that broader implementation was being held back by a lack of consensus over evidentiary standards, inefficient and inconsistent regulatory and reimbursement approaches, the need for a framework for collecting patient data, and translating that data into improved patient outcomes.

Companies, Health Systems Commit to Data Interoperability

Companies that provide 90 percent of electronic health records used by U.S. health care organizations have agreed to improve the flow of health information for consumers and health care providers, HHS officials said.

 

Study: California Hospitals with Low Volumes of Surgeries Associated with Higher Risks

In California, nearly 75 percent of the state’s hospitals performed only one or two surgeries when treating one of 11 selected cancer types in 2014, according to a report from the California Health Care Foundation.

The report linked the low hospital surgery volumes with higher rates of mortality and complications, while evaluating cancers of the bladder, brain, breast, colon, esophagus, liver, lung, pancreas, prostate, rectum and stomach.

Obituary

UNMC Scientist Michael Brattain Dies Unexpectedly at Age 68

Michael Brattain, University of Nebraska Medical Center Eppley Institute professor and associate director for basic research in the Fred & Pamela Buffett Cancer Center, died unexpectedly in his sleep March 5. He was 68.

“Mike was a brilliant scientist who had a prolific scientific career,” said Kenneth Cowan, director of the Eppley Institute and the Buffett Cancer Center. “Mike’s experience and input was extremely valuable to me in many areas within the Buffett Cancer Center.

In Brief
  • Sadik Esener to lead OHSU Center for Early Detection Research

  • Jorge Lopez Jr. Named MSKCC General Counsel

  • Aron Parekh receives research grant from American Cancer Society
  • Robin Mjelle receives grant from Addario Foundation and International Association for the Study of Lung Cancer

  • William Grady receives grant from DeGregario Family Foundation and the Price Family Foundation

  • Baylor College of Medicine and Baylor Scott & White Health enter collaboration

  • Tufts Medical Center and New England Cancer Specialists form affiliation

  • UC San Francisco and Berkeley Lights Inc. form collaboration

Drugs and Targets
  • FDA Approves Xalkori in NSCLC with ROS-1 mutations

  • FDA Approves American College of Radiology Digital Mammography QC Manual

  • Regulatory Authorities in Six Countries approve Yondelis

  • China Food and Drug Administration Approves CINtec PLUS Cytology Test

  • Veritas Genetics introduces whole genome platform for under $1,000

 

20160311 - Mar. 11, 2016
BREAKING NEWS – MARCH 8, 2016 

In an Experiment, CMS Will Vary Part B Drug Payments by Providers’ ZIP Codes

Is Average Sales Price plus 6 percent the right amount to pay doctors under the Medicare Part B program?

Would a smaller margin diminish what may be an incentive to prescribe the most expensive drugs on the market? With clinical performance being equal, or close enough to equal, is it not better for the doctor’s wallet to bill 6 percent of the highest possible ASP available?

In a move that immediately set off an explosion in the cancer field, the Centers for Medicare and Medicaid Services is on the verge of announcing a Part B Drug Payment Demo, a project where ASP add-ons would vary based on zip codes.

    20160308 - Mar. 8, 2016
    ISSUE 9 – MARCH 4, 2016PDF



    NCI Developing Mouse Models To Succeed NCI-60 Cell Lines

    The NCI-60, a panel of 60 cancer cell lines that have become the Rosetta Stone for the development of anticancer drugs, may be entering its twilight years as NCI develops new, and more expansive, patient-derived xenografts, or PDX models.

    For over 25 years, the NCI-60, a set of about a dozen tissue types—leukemia, non-small cell lung, small cell lung, colon, CNS, melanoma, ovarian, renal, and breast—have been used to perform initial screens on over 100,000 compounds.

     

    Conversation with The Cancer Letter

    Doroshow: Evidence Suggests PDX Models Come Closer to Simulating Human Cancer

    NCI is developing patient-derived xenograft mouse models as a potential substitute for the NCI-60 cell lines, a standard screen which experts say can no longer keep up with advances in cancer research and targeted molecular therapy.

    “The goal is to try to understand whether these new models will be more successful in providing a better reflection of the underlying biology in the context of the clinical history and treatment history of patients from whence the tissues came,” said James Doroshow, director of the NCI Division of Cancer Treatment and Diagnosis and deputy director for clinical and translational research.

    Slamming the Door

    Part VI: The Provost’s Choice

    After my conversation with Gilman, I called MD Anderson and asked to talk with somebody about the $18 million grant for a biotech incubator.

    First, folks at the press shop told me that they view the controversy arising from the application as CPRIT’s problem.

    Let’s see: the wife of president of MD Anderson gets a grant seemingly out of turn, causing a political disaster, and this is not an MD Anderson problem?

    National Academy of Medicine Publishes Report on Categorizing Different Ovarian Cancers

    Ovarian cancer should not be categorized as a single disease, but as many different cancers involving the ovary, according to a report published by the National Academy of Medicine.

    Questions remain on how and where various ovarian cancers arise, said the report that also presents research opportunities for reducing the number of women who are diagnosed with or die from ovarian cancers. Roughly two-thirds of women are diagnosed at an advanced stage when the cancer has already spread beyond the ovary, of which less than 30 percent survive past five years. The report was also sponsored by the Centers for Disease Control and Prevention.

    Funding Opportunity

    FDA Providing $2 Million for Natural History Studies in Rare Diseases

    FDA will provide $2 million in two to five research grants for the study of the natural history of rare diseases. The objective of the grants is to expedite the development of products for these conditions.

    The Feb. 29 announcement marks the first time FDA will provide funding through its Orphan Products Grants to collect data on the progression of specific rare diseases in individuals over time.

    In Brief

    • Joan Massagué wins Pezcoller-AACR International Cancer Research Award

    • David Weiner named executive vice president at The Wistar Institute

    • Douglas Levine named director of gynecologic oncology at NYU Perlmutter Cancer Center
    • Lauren Streicher joins Northwestern Medical Group as medical director

    • Michael Bukosky appointed chief operating officer of USMD Holdings Inc.

    • International Cancer Genome Consortium authorizes 1,000th user

    • IBM and New York Genome Center to collaborate using Watson technology

    • Vantage Oncology LLC acquired by McKesson Specialty Health

     Drugs and Targets

    • Imbruvica granted approval for first-line CLL patients

    • Health Canada approves Opdivo for metastatic NSCLC

    • FDA grants orphan drug designation to SELLAS’s WT1 cancer vaccine

    • EMA grants orphan drug designation to venetoclax

    • FDA and EMA grant orphan designations to FLAG-003 for glioma

    • Merck KGaA, Pfizer and Verastem enter into avelumab research agreement

    • NanoString Technologies and Merck to collaborate on Keytruda assay

     

    20160304 - Mar. 4, 2016
    February 2016PDF

     

    Leukemia

    Phase III Blincyto Study Stopped Early After Meeting OS Primary Endpoint

    A phase III study of Blincyto met its primary endpoint of overall survival in patients with acute lymphoblastic leukemia following a prespecified interim analysis. The study was stopped early.

    The randomized, open-label TOWER study evaluated the efficacy of Blincyto (blinatumomab) versus the standard of care in adult patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

    Patients were randomized in a 2:1 ratio to receive Blincyto or treatment with investigator choice of one of four protocol defined SOC chemotherapy regimens.

       

      Soft Tissue Sarcoma

      Halaven Study Improves Overall Survival In Liposarcomas and Leiomyosarcomas

      Full results from a phase III study showed improved median overall survival in unresectable locally advanced liposarcomas and leiomyosarcomas in patients receiving Halaven (eribulin), compared to dacarbazine.

      The clinical trial, study 309, included data from 452 adults, and was published in The Lancet, which also published an editorial discussing the study results.

      The study compared patients treated with eribulin mesilate (1.4 mg/msquared intravenously on days 1 and 8) and those treated with dacarbazine (850 mg/msquared, 1000 mg/msquared, or 1200 mg/msquared [dose dependent on center and clinician] intravenously on day 1). Additional endpoints included progression-free survival and quality of life.

         

        Breast Cancer

        OBI-822/821 Phase II/III Study Does Not Meet PFS Endpoint, But Shows Positive Results In Patients with Immune Response

        OBI Pharma Inc., announced topline results from a phase II/III study of OBI-822/821 (formerly OPT822/OPT821), which evaluated the clinical benefit and immunogenicity in patients with metastatic breast cancer. The study did not meet the primary efficacy endpoint of progression-free survival.

        However, patients who demonstrated an immune response showed highly significant improvement in progression-free survival and the secondary endpoint of overall survival is trending towards statistical significance. OBI-822/821 was generally well tolerated with no major safety concerns. Full results will be presented at an upcoming international scientific conference.

           

          Pancreatic Cancer

          Two Studies Evaluate 2nd Line Treatments Following Abraxane

           

          Non-Small Cell Lung Cancer

          Gilotrif Improves PFS Compared to Iressa in Phase IIb Trial

           

          Thyroid Cancer

          Study: Afirma Genomic Test Can Reduce Unnecessary Fine Needle Aspiration Biopsies

           

          NCI CTEP-Approved Trials for the Month of February

           

          Drugs and Targets

          • Gazyva Combination Approved In Follicular Lymphoma
          • FDA approves Afinitor for GI and lung NETs
          • Venetoclax receives third FDA Breakthrough Designation
          • FDA grants breakthrough designation to PKC412 (midostaurin)
          • FDA grants orphan drug designation to tazemetostat for malignant rhabdoid tumors
          • FDA grants orphan drug designation to CD101 IV for candidema
          20160229 - Feb. 29, 2016
          ISSUE 8 – FEB. 26, 2016PDF



          Slamming the Door

          Part V: Gilman’s Resignation

          Gilman’s letter of resignation, dated May 8, 2012, concludes with a hard slam:

          “The purpose of this letter is to indicate my intention to resign from CPRIT, effective (with your permission) on October 12, 2012. At that time I will have worked for CPRIT for over three years—I believe longer than originally anticipated.

          “During that time we have launched strong programs because funding decisions have been based on high-level competitions, where the judges have been some of the best cancer researchers and physicians in the country—free of conflicts of interest and all coming from outside of Texas.

          “It was exciting to launch this program, to design effective requests for applications, and to oversee the peer review process.



          Capitol Hill Briefing Focuses on Moonshot’s Provision to Integrate FDA Cancer Portfolio

          When the White House proposed a $1 billion startup fund for the National Cancer Moonshot, a largely unexpected directive to reform FDA raised many questions among oncology insiders.

          The agency will create a virtual Oncology Center of Excellence, the administration proposals and budget documents state.

          Alas, nobody can claim to understand what “virtual” means in this context, and how the $75 million in proposed fiscal 2017 mandatory funds would be used to “leverage the combined skills of regulatory scientists and reviewers with expertise in drugs, biologics, and devices.”

          In Brief

          • Laurie Glimcher named president and CEO at Dana-Farber

          • Robert Califf confirmed as FDA Commissioner

          • Mandi Pratt-Chapman named associate center director at GW Cancer Center
          • Steve Limentani named VP and chief research officer at Mission Health

          • Robert Korngold receives lifetime achievement award from the American Society for Blood and Marrow Transplantation

          • Breast Cancer Research Foundation expands research program with Pfizer portfolio

          • Bharat Aggarwal has seven papers retracted from Biochemical Pharmacology 

          • Commission on Cancer honors 27 programs for outstanding achievement

          • Kids V Cancer named one of top 10 most innovative companies

          • Indiana University Simon Cancer Center receives grant from Kay Yow Cancer Fund
          Drugs and Targets

          • FDA approves Gazyva for follicular lymphoma

          • FDA approves Afinitor for GI or lung neuroendocrine tumors

          • FDA grants Breakthrough Designation to PKC412 (midostaurin)

          20160226 - Feb. 26, 2016
          ISSUE 7 – FEB. 19, 2016PDF



          Should ODAC Vote? Yes? No? Undecided?

          At its most recent meeting, in July 2015, the FDA Oncologic Drugs Advisory Committee voted…

          No, it didn’t vote!

          Breaking with a long-standing tradition, the agency asked ODAC members to “discuss” the key questions of risk vs. benefit of an experimental therapy instead of reducing their answers to a yea-or-nay vote. Agency officials are mum on the subject of whether not voting has become a thing.

          News Analysis

          Rejected Therapy Reveals Inconsistency of FDA Procedures for Drugs, Immunotherapies

          Reform of the FDA oncology program is emerging as the immediately tangible element of the Obama administration’s moonshot program.With a modest $75 million commitment, the administration may be able to standardize the manner in which elements of modern cancer care are reviewed and approved by the regulatory agency (The Cancer Letter, Feb. 12).

          As it stands, immunological and cellular cancer therapies as well as diagnostics don’t go through the same review procedures as cancer drugs and biologics.

          Slamming the Door

          Part IV: Nobel Laureate in Crosshairs

          In early 2012, Gilman was under the impression that CPRIT was functioning smoothly.

          Then, to his surprise, the first of a series of controversies surfaced.

          CPRIT’s peer reviewers had evaluated 40 applications for Multi-Investigator Research Applications, the largest CPRIT grants designed to fund team science, recommending that seven of these project receive funding. This was no small undertaking. The applications described multiple projects and core facilities.

          Report: Medicare Pays 340B Hospitals Less Part B Drug Reimbursement

          A group advocating for the 340B Drug Discount Program examined the widely held belief that health care organizations enrolled in the controversial federal program receive significantly higher reimbursement for drugs than institutions that do not take part in the program.Previously, a July 2015 study by the Government Accountability Office found that, per beneficiary, Medicare Part B drug spending was indeed higher at 340B hospitals than at non-340B hospitals.

          In Brief

          • Arnold Foundation gives $7.2 million to drug pricing programs
          • Joan Schiller named deputy director at Inova Cancer Institute
          • Jeannie Lee receives 2016 Lurie Prize
          • Canadian Cancer Society names four excellence award winnerse
          • Marcia McNutt named president of National Academy of Sciences
          • Medical Oncology & Hematology Associates of Northern Virginia joins Inova Medical Group

           

          20160219 - Feb. 19, 2016
          ISSUE 6 – FEB. 12, 2016PDF



          Obama’s $4.1 Trillion Budget Proposes Mandatory Funds for $1 Billion Moonshot

          President Barack Obama Feb. 8 unveiled his budget proposal for the 2017 fiscal year—a $4.1 trillion spending blueprint that is unlikely to be passed by a Republican-controlled Congress.

          The administration’s proposal appears to cut the NIH existing budget by $1 billion in discretionary funding and makes up the difference with mandatory funding.

          In a joint snub, the House and Senate budget committees declined to hold a hearing for Shaun Donovan, the director of the Office of Management and Budget. The move marks the first time in 41 years that Congress has refused to review a president’s budget.

          Conversation with The Cancer Letter

          Sigal: FDA Should Consolidate Cancer Portfolio

          President Barack Obama’s Feb. 8 budget request for fiscal year 2017 slates $75 million in additional funding for FDA for the creation of a virtual Oncology Center of Excellence.

          The proposal is arguably the most tangible component of Vice President Joe Biden’s National Cancer Moonshot program, which aims to double progress in cancer research and drug development over the next five years.

          Slamming the Door – How Al Gilman Taught Texas a Lesson in Science

          Part III: 18,000 Bosses

          Between the fall of 2011 and the spring of 2012, I watched MD Anderson from afar, and I didn’t think about CPRIT at all.

          Friends who attended early meetings with Ronald DePinho soon after he became MD Anderson’s president said that he was literally grading presentations made to him by faculty members and administrators.

          “This was a C-,” he would say.

          It was difficult to get a B.

          In Brief

          • Miami Cancer Institute joins MSK Cancer Alliance
          • Ramalingam named deputy director of Winship Cancer Institute
          • David McConkey appointed director of Johns Hopkins Bladder Institute
          • Sylvester Comprehensive Cancer Center creates two endowed chairs
          • Pat Keel appointed CFO of St. Jude
          • Paul Vanveldhuisen named COO of The Emmes Corporation
          • American Urological Association, Urology Care Foundation and Chesapeake Urology Associates form partnership
          • Bonnie J. Addario Foundation launches second phase of crowdsourcing challenge
          • ESPN’s Jimmy V Week for Cancer Research raises $3.2 million
          Drugs and Targets

          • FDA grants orphan designation to tazemetostat
          • PDS Biotechnology signs CRADA with NCI
          • FDA grants orphan designation to antifungal drug candidate CD101 IV

           

          20160212 - Feb. 12, 2016
          ISSUE 5 – FEB. 5, 2016PDF



          Slamming the Door

          Part II: Cancer’s Butt

          CPRIT’s review process appeared to have become a major annoyance to those who wanted to redraft the criteria for dispensing the princely sum of $300 million a year. Texas geography and Texas politics did matter—a lot.

          The cross-state competition between MD Anderson Cancer Center and UT Southwestern Medical Center proved to be especially important.

          MD Anderson has long been a clinical powerhouse, the kind of place you go with a complicated cancer. If it ramped up its basic science, the cancer center would be better positioned to understand the origins of cancer and make more fundamental contributions to treatment of cancers, including discovering useful drug candidates and moving them from the bench to the clinic.

          White House Promises $1 Billion for Cancer MoonshotThe White House announced a $1 billion initiative Feb. 1 to jumpstart the national cancer moonshot program—an ambitious proposal first announced by President Barack Obama during his final State of the Union address.

          Vice President Joe Biden, whose son Beau died of brain cancer in May 2015 at age 46, is leading the program, which aims to achieve a decade’s worth of progress within the next five years.

          FDA Releases New Opioid Plan as Senators Stall Robert Califf’s Confirmation as Commissioner

          Robert Califf, the nominee to serve as the next FDA commissioner, and other FDA leaders called for a broad plan to reassess the agency’s approach to prescription opioid medications. The move comes as Senators block a vote on his confirmation for the top post.

          Sen. Edward Markey (D-Mass.) and Democratic presidential candidate Sen. Bernie Sanders of Vermont have both placed procedural holds on Califf’s confirmation, citing the agency’s policies and methods for approving opioids, as well as Califf’s financial ties to the pharmaceutical industry.

          In Brief

          • Lonial named head of hematology and oncology at Winship Cancer Institute
          • Stand Up To Cancer Canada announces brain cancer dream team
          • Keith Hanson McGregor named CEO of ESMO
          • M. Beatriz Currier joins Miami Cancer Institute
          • H. Benjamin Harvey and Courtney Moreno receive ACR fellowship
          • Van Andel Research Institute-SU2C Dream Team trial enters phase II
          Drugs and Targets

          • Venetoclax receives third FDA breakthrough designation
          • FDA tells Telesta they need another phase III MCNA trial
          • Mayo Clinic collaborates with Morphotek in triple-negative breast cancer study.
          20160205 - Feb. 5, 2016
          January 2016PDF

           

          Melanoma

          Phase III Trial Binimetinib Increases PFS in NRAS-Mutant Melanoma vs. Dacarbazine

          Array BioPharma reported top-line results from the ongoing phase III clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, demonstrating that the study met its primary endpoint of improving progression-free survival when compared with dacarbazine treatment.

          The median PFS on the binimetinib arm was 2.8 months versus 1.5 months on the dacarbazine arm (HR=0.62, 95% CI 0.47-0.80, p < 0.001). Binimetinib was generally well-tolerated and the adverse events reported were consistent with previous results in NRAS melanoma patients. Binimetinib is a small molecule MEK inhibitor which targets key enzymes in the RAS/RAF/MEK/ERK pathway.

          Breast Cancer

          Survey of Breast Cancer Cell Function Identifies New Drug Uses, Combinations

          Researchers conducted a large analysis of breast cancer cell function, saying the results suggest dozens of new uses for existing drugs, new drug discovery targets, and new drug combinations.

          “This study represents the largest survey yet of how the genetic changes in breast cancer cells interfere with pathways critical to their growth and survival, pathways that might be targeted by combinations of new or existing drugs,” said lead study author Benjamin Neel, director of the Perlmutter Cancer Center at NYU Langone Medical Center.

          The study results were published in the journal Cell. The researchers combined genetic analyses of more breast cancer cell types than studied previously, new statistical methods, and comparisons with databases of molecular signatures and the effects of anti-cancer drugs.

          Ovarian Cancer

          Trial of 200,000 Women Shows Screening Can Reduce Mortality by 20 Percent

          One of the largest randomized trials ever has concluded that ovarian cancer screening may reduce ovarian cancer mortality by an estimated 20 percent after follow up of up to 14 years, but researchers say longer follow-up is needed to determine the ultimate mortality reduction and if screening the general population is cost effective.

          The United Kingdom Collaborative Trial of Ovarian Cancer Screening enrolled 202,638 women, aged 50-74 years, between 2001 and 2005 through 13 trial centers in England, Northern Ireland and Wales. The study results were published in The Lancet.

          The study tested the hypothesis that screening for ovarian cancer in the general population can reduce disease mortality without significant harm, in line with screening programs for other cancers.

          Colorectal Cancer

          Cervical Cancer

          Analysis Evaluates Moore Criteria for Bevacizumab Effectiveness

          NCI CTEP-Approved Trials for the Month of January
          Drugs and Targets

          • Opdivo-Yervoy combination granted accelerated approval in metastatic melanoma
          • Halaven approved for unresectable or metastatic liposarcoma
          • Zepatier approved for chronic hepatitis C
          • Health Canada grants conditional approval to Blincyto in Ph- acute lymphoblastic leukemia
          • FDA grants breakthrough designations to BI1482694 (HM61713) and venetoclax
          • Priority review granted to lenvatinib in renal cell carcinoma
          20160201 - Feb. 1, 2016
          ISSUE 4 – JAN. 29, 2016PDF



          Slamming the Door

          How Al Gilman Taught Texas A Lesson in Science

          Alfred Gilman’s approach to distributing public funds wasn’t particularly difficult to understand: he wanted to pay for the best science available. Period.

          The pot of money entrusted to Gilman was vast. In 2007, Texas voters approved the largest investment in cancer research outside the federal government: $3 billion, to be spent over 10 years. By way of comparison, NCI grants going to Texas researchers and institutions added up to $240 million a year. CPRIT more than doubled that money. Only Texans were eligible to apply.

          Gilman accepted the CPRIT job at age 68, because he thought that it would be a significant contribution to a major research effort, and a nice way to finish out a long career.

          Sixty-Nine Cancer Centers Urge HPV VaccinationIn an unprecedented move, 69 NCI-designated cancer centers have come together to advocate for HPV vaccination as a preventive measure against many HPV-related cancers.

          “HPV vaccination is our best defense in stopping HPV infection in our youth and preventing HPV-related cancers in our communities,” the centers said in a consensus statement published Jan. 27. “The HPV vaccine is cancer prevention.”

          PCORI Passes $1.2 Billion in Total Research Funding

          The Patient-Centered Outcomes Research Institute approved $70 million for nine new patient-centered research projects focused on conditions including ductal carcinoma in situ, diabetes, chronic lung disease and migraines.

          With these latest awards, PCORI has now approved or awarded more than $1.2 billion in research funding.

          In Brief

          • Minesh Mehta named deputy director at Miami Cancer Institute
          • Carmen Solórzano named chief of Division of Surgical Oncology at Vanderbilt
          • Judy Keen named ASTRO director of scientific affairs
          • Tara Yates joins Wistar Institute as director of communications
          • Ovarian Cancer National Alliance and Ovarian Cancer Research Fund merge
          • UC San Diego Health selects e+CancerCare to operate Chula Vista radiation center
          • Harvard Business School launches Precision Trials Challenge
          Drugs and Targets

          • FDA expands Opdivo-Yervoy Label with accelerated approval in melanoma
          • Halaven approved for unresectable or metastatic liposarcoma
          • Zepatier approved for treatment of chronic hepatitis C
          20160129 - Jan. 29, 2016
          Page 8 of 22« First...45678910111213...20...Last »